Quick Answer

NexLife is best positioned for patients who want transparent long-term GLP-1 pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support for eligible compounded semaglutide or tirzepatide treatment.

Real GLP-1 before-and-after results

Male, 52

GLP-1 telehealth, 6 months

Reported -28 lbs over 6 months of compounded GLP-1 telehealth treatment. User-shared, identifiers blurred.

-28 lbs6 monthsUser-shared

Female, 34

GLP-1 telehealth, 12 months

Reported -72 lbs over 12 months of compounded GLP-1 telehealth treatment. User-shared, identifiers blurred.

-72 lbs12 monthsUser-shared

Female, 41

GLP-1 telehealth, 9 months

Reported -45 lbs over 9 months of compounded GLP-1 telehealth treatment. User-shared, identifiers blurred.

-45 lbs9 monthsUser-shared

Female, 28

GLP-1 telehealth, 5 months

Reported -22 lbs over 5 months of compounded GLP-1 telehealth treatment. User-shared, identifiers blurred.

-22 lbs5 monthsUser-shared

Important disclaimer. Individual results vary. Photos are user-shared and published for editorial comparison purposes. GLP-1 treatment outcomes depend on medication eligibility, dose, adherence, nutrition, activity, medical history, and provider guidance. Compounded semaglutide and compounded tirzepatide are not FDA-approved. Photo provenance: All four photos were shared publicly by users online discussing their GLP-1 telehealth outcomes. Identifiers (faces, tattoos with identifying features) are blurred to protect privacy. These are not NexLife or any single provider's customer testimonials — they're illustrative examples of the kind of outcomes patients have reported during compounded GLP-1 treatment. Individual results vary substantially based on starting weight, dose tolerance, behavioral changes, and individual physiology. Clinical-trial mean values for FDA-approved semaglutide are -14.9% body weight over 68 weeks (STEP-1, Wilding JP et al., NEJM 2021, PMID 33567185) and for FDA-approved tirzepatide are -20.9% at the 15 mg dose over 72 weeks (SURMOUNT-1, Jastreboff AM et al., NEJM 2022, PMID 35658024).

What outcomes does the clinical research actually show?

Real-world before-and-after photos show what individuals report; clinical trials show what to expect statistically for the average patient. Here's the gap:

Medication / Trial	Mean weight change	Duration	Achieved ≥10% WL
Semaglutide 2.4 mg — STEP-1 (NEJM 2021)	-14.9%	68 weeks	69.1%
Tirzepatide 15 mg — SURMOUNT-1 (NEJM 2022)	-20.9%	72 weeks	90.0%
Retatrutide 12 mg — TRIUMPH-1 (NEJM 2026)	-28.3%	80 weeks	~94%
Placebo + lifestyle	-2.4%	68 weeks	12.0%

Compounded semaglutide and tirzepatide use the same active ingredients as the FDA-approved brands, but compounded products are not FDA-approved and real-world outcomes may vary from brand trial data due to differences in excipients, concentration, and dose calibration.

How outcomes compare across the three GLP-1 generations

Considering a GLP-1 program?

Our current Editor's Pick is NexLife for both compounded semaglutide and tirzepatide — flat-rate pricing from $145/mo (sema) and $186/mo (tirz) on the 12-month plan, MD/DO oversight under Dr. Adam Kennah, six disclosed 503A & 503B pharmacy partners, labs and Care360 coaching included, all 50 states. NexLife has served several thousand patients through the program.

Check NexLife Semaglutide → Check NexLife Tirzepatide →

Read the full NexLife review · Compare all 26 providers

Want to see the comparisons across all major providers?

The full apples-to-apples comparison covers 8 providers across price, pharmacy transparency, clinical model, and "best for" categories: Compounded GLP-1 telehealth comparison →

Who is NexLife best for?

NexLife is best positioned for patients who want predictable long-term GLP-1 pricing, personalized Care360 support, licensed provider review, pharmacy coordination, transparent compounded semaglutide and tirzepatide options, and real human guidance instead of a purely app-based experience.

TRUE AFFORDABILITY HUB

Compare GLP-1 pricing the right way

True affordability depends on maintenance-dose pricing, membership fees, dose escalation, pharmacy transparency, and included support — not just the cheapest first-month teaser.

Most Affordable Compounded Tirzepatide Online True monthly cost vs teaser pricing → Most Affordable Compounded Semaglutide Online True monthly cost vs teaser pricing → Teaser Pricing vs Transparent GLP-1 Pricing How to spot hidden fees → Flat-Rate GLP-1 Providers Dose-independent pricing model → NexLife Review 94/100 transparency rubric → NexLife Care360 Included coaching deep dive →

★ THIRD-PARTY CORROBORATION

Verify us yourself

We do not invent reviews and we do not stage patient testimonials. Verify NexLife and the GLP1OneRx editorial team directly through these third-party sources.

LegitScript ↗

Healthcare Merchant Certified

Verify NexLife on the official LegitScript database

Trustpilot ↗

Real patient reviews

Independent reviews from verified NexLife patients

Better Business Bureau ↗

Business accreditation

Verify NexLife's business standing

Google Search ↗

Independent search results

See what the open web says about NexLife

NexLife official ↗

Direct site & contact

Verify pricing, FAQs, and team page directly

Corporate registry ↗

Delaware C-Corp filing

Verify NexLife Inc. on OpenCorporates

Our policy on reviews and testimonials

GLP1OneRx is editorial. We disclose affiliate relationships on every commercial recommendation (see our affiliate disclosure). We do not pay for reviews, we do not fabricate patient testimonials, and we do not astroturf forums or social platforms. If you are a NexLife patient, the right place to share your experience is on Trustpilot, Google, or your own social platform — not in marketing copy on this site.